Evidence map›Paper›PMID 27455834›Full record

ArticleJournal of nanobiotechnology2016

Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting.

Marie Plissonneau, Jonathan Pansieri, Laurence Heinrich-Balard, Jean-François Morfin, Nathalie Stransky-Heilkron, Pascaline Rivory, Pierre Mowat, Mireille Dumoulin, Richard Cohen, Éric Allémann and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Review
  3. Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils.Protein science : a publication of the Protein Society · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. AGuIXThe British journal of radiology · 2019
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Marie PlissonneauNano-H S.A.S, 38070, Saint Quentin Fallavier, France.
Jonathan PansieriLaboratoire de Chimie et Biologie des Métaux, Université Grenoble Alpes, CEA Life Science Division, CNRS, 17 rue des Martyrs, 38054, Grenoble Cedex 9, France.
Laurence Heinrich-BalardUniversité de Lyon, Lyon, France.
Jean-François MorfinCentre de biophysique moléculaire, UPR 4301, Rue Charles Sadron CS 80054, 45071, Orléans Cedex 2, France.
Nathalie Stransky-HeilkronSchool of pharmaceutical Sciences, University of Geneva, University of Lausanne Pharmaceutical technology, Quai Ernest-Ansermet 30, 1211, Geneva, Switzerland.
Pascaline RivoryUniversité de Lyon, Lyon, France.
Pierre MowatLaboratoire de Chimie et Biologie des Métaux, Université Grenoble Alpes, CEA Life Science Division, CNRS, 17 rue des Martyrs, 38054, Grenoble Cedex 9, France.
Mireille DumoulinCentre for Protein Engineering, Laboratory of Enzymology and Protein Folding Institut of Chemistry, B6 University of Liege Sart Tilman, 4000, Liege, Belgium.
Richard CohenUniversité de Lyon, Lyon, France.
Éric AllémannSchool of pharmaceutical Sciences, University of Geneva, University of Lausanne Pharmaceutical technology, Quai Ernest-Ansermet 30, 1211, Geneva, Switzerland.
Éva TόthCentre de biophysique moléculaire, UPR 4301, Rue Charles Sadron CS 80054, 45071, Orléans Cedex 2, France.
Maria Joao SaraivaMolecular Neurobiology Group, Institute of Biology, Molecular and Cellular, R. Campo Alegre 823, 4150, Porto, Portugal.
Cédric LouisNano-H S.A.S, 38070, Saint Quentin Fallavier, France.
Olivier TillementInstitut Lumière Matière, UMR5306 CNRS Université Claude Bernard Lyon 1, Domaine Scientifique de La Doua, 2 rue Victor Grignard, 69622, Villeurbanne Cedex, France.
Vincent ForgeLaboratoire de Chimie et Biologie des Métaux, Université Grenoble Alpes, CEA Life Science Division, CNRS, 17 rue des Martyrs, 38054, Grenoble Cedex 9, France.
François LuxInstitut Lumière Matière, UMR5306 CNRS Université Claude Bernard Lyon 1, Domaine Scientifique de La Doua, 2 rue Victor Grignard, 69622, Villeurbanne Cedex, France.
Christel MarquetteLaboratoire de Chimie et Biologie des Métaux, Université Grenoble Alpes, CEA Life Science Division, CNRS, 17 rue des Martyrs, 38054, Grenoble Cedex 9, France. christel.marquette@cea.fr.ORCID http://orcid.org/0000-0002-0640-3025
Université Claude Bernard Lyon 1 · FRCentre National de la Recherche Scientifique · FRCentre de Biophysique Moléculaire · FRUniversity of Geneva · CHL3 Médical (France) · FRUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmyloidoses are characterized by the extracellular deposition of insoluble fibrillar proteinaceous aggregates highly organized into cross-β structure and referred to as amyloid fibrils. Nowadays, the diagnosis of these diseases remains tedious and involves multiple examinations while an early and accurate protein typing is crucial for the patients' treatment. Routinely used neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) using Pittsburgh compound B, [(11)C]PIB, provide structural information and allow to assess the amyloid burden, respectively, but cannot discriminate between different amyloid deposits. Therefore, the availability of efficient multimodal imaging nanoparticles targeting specific amyloid fibrils would provide a minimally-invasive imaging tool useful for amyloidoses typing and early diagnosis. In the present study, we have functionalized gadolinium-based MRI nanoparticles (AGuIX) with peptides highly specific for Aβ amyloid fibrils, LPFFD and KLVFF. The capacity of such nanoparticles grafted with peptide to discriminate among different amyloid proteins, was tested with Aβ(1-42) fibrils and with mutated-(V30M) transthyretin (TTR) fibrils.

resultsThe results of surface plasmon resonance studies showed that both functionalized nanoparticles interact with Aβ(1-42) fibrils with equilibrium dissociation constant (Kd) values of 403 and 350 µM respectively, whilst they did not interact with V30M-TTR fibrils. Similar experiments, performed with PIB, displayed an interaction both with Aβ(1-42) fibrils and V30M-TTR fibrils, with Kd values of 6 and 10 µM respectively, confirming this agent as a general amyloid fibril marker. Thereafter, the ability of functionalized nanoparticle to target and bind selectively Aβ aggregates was further investigated by immunohistochemistry on AD like-neuropathology brain tissue. Pictures clearly indicated that KLVFF-grafted or LPFFD-grafted to AGuIX nanoparticle recognized and bound the Aβ amyloid plaque localized in the mouse hippocampus.

conclusionThese results constitute a first step for considering these functionalized nanoparticles as a valuable multimodal imaging tool to selectively discriminate and diagnose amyloidoses.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsDisease Models, AnimalFemaleGadoliniumGene ExpressionHippocampusHumansKineticsMagnetic Resonance ImagingMetal NanoparticlesMiceMice, TransgenicMutationPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)GadoliniumPeptide FragmentsPeptidesPrealbuminAlzheimer’s diseaseAmyloid imagingBeta-amyloid fibrilsGadolinium based nanoparticlesMRI contrast agentPeptide-targeting

Identifiers

PMID27455834
PMCPMC4960888
OpenAlexW2486781004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.